ATS 2019 Virtual Final Program

P145 Significance of Blood Eosinophil Count in Stable COPD/ W.B. LeMaster, D. Markovic, S. Ingersoll, R.G. Buhr, M. Flynn, W. Toppen, M. Dembek, M. Villarreal, R. McGill, J.J.A. Johnston, J.A. Belperio, B. Milenkovic, H. Phee, C.B. Cooper, I. Barjaktarevic, Los Angeles, CA, p.A1581 P146 Biomass Exposure Effects in COPD Patients Under 40: Substudy of a Nationwide Survey/ S. Qumu, G. Xu, F. Dong, L. Wang, T. Yu, H. Niu, M. Lu, T. Yang, C. Wang, Beijing, China, p.A1582 P147 APR-DRG Classifications as Predictors of Thirty-Day Inpatient Readmissions in Patients with COPD/ T.A. D’Amico, R.L. ZuWallack, R.E. Crowell, D. Ibrahim, Farmington, CT, p.A1583 P148 Benzodiazepine Use and Clinical Outcomes Among Adult Outpatients with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study/ N. Tentoni, A. Ferraris, F. Angriman, B.L. Ferreyro, J. Maritano Furcada, D. Giunta, Buenos Aires, Argentina, p.A1584 P149 Comparison of Weekend and Weekday Physical Activity Patterns in Chronic Obstructive Pulmonary Disease (COPD) and Non-COPD Participants by Daily Activity Level/ N. Locantore, R.P. Bowler, M. Marschall, S. Chen, Y. An, M. Allinder, D. Mohan, Collegeville, PA, p.A1585 P150 Blood Eosinophil Counts in Patients with Marked FEV1 Reversibility and Fixed Airflow Obstruction/ S. Riley, R. Al-Lehebi, S. Gurupatham, E. Grbac, M.B. Stanbrook, Toronto, Canada, p.A1586 P151 Correlation of Oxidative Stress and Antioxidant Enzymes with Mortality in Critically Ill Mechanical Ventilated Patients/ R. Guleria, S. Arora, P. Tiwari, A. Mohan, M. Kalaivani, New Delhi, India, p.A1587 P152 Benefits of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) in Reducing Exacerbation Risk in Patients with Moderate-to-Very Severe COPD: A Pooled Analysis of the PINNACLE Studies/ S. Sethi, B.J. Lipworth, G.T. Ferguson, S. Arora, M. Jenkins, A. Maes, U.J. Martin, C. Reisner, Buffalo, NY, p.A1588 P153 HIV Infected Patients with Chronic Respiratory Symptoms Should Be Proactively Screened for Chronic Obstructive Pulmonary Disease, Results from a Cross Sectional Study/ A. Ddungu, B. Kirenga, F. Semitala, B. Castelnuovo, C. Sekaggya-Wiltshire, W. Worodria, Kampala, Uganda, p.A1589 P154 Association of Beta-2 Adrenergic Receptor (ADRB2) Gene Polymorphisms with Long-Term Clinical Course of COPD in Japanese Population/ N. Takei, M. Suzuki, H. Makita, S. Konno, K. Shimizu, H. Kimura, H. Kimura, M. Nishimura, Sapporo, Japan, p.A1590 P155 COPD Assessment Test (CAT) Score Is Associated with Risk of Future Exacerbation: An Analysis from the IMPACT Trial/ M.A. Stiegler, B. Thomashow, G.J. Criner, M.T. Dransfield, D.M.G. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, F.J. Martinez, D. Singh, M. Tabberer, R.A. Wise, D.A. Lipson, Research Triangle Park, NC, p.A1591 P156 Emergency Room Visits and Hospital Readmissions for Acute Exacerbations of COPD Are Similar Among Homeless and Non-Homeless Veterans with Access to Dental Care in Chicago/ I. Imayama, M. Tole, G. Callison, I. Rubinstein, Chicago, IL, p.A1592 P157 Relations Between Clinical COPD Phenotypes and 6-Min Walking Distance/ P.-R. Burgel, T. Perez, G. Deslée, J.-L. Paillasseur, N. Roche, Paris, France, p.A1593 P158 Prevalence of Chronic Obstructive Pulmonary Disease (COPD) Among Patients Successfully Treated for Pulmonary Tuberculosis in Ethiopia/ A.B. Binegdie, C.B. Sherman, M. Getachew, N. Scluger, Addis Ababa, Ethiopia, p.A1594 P159 The Profile of COPD Patients with Prolonged Hospitalizations: A Retrospective Analysis of 200 Admissions/ G. Epstein Shochet, E. Abd El Qader, L. Israeli-Shani, Z. Dovrish, O. Wand, D.A. King, D. Shitrit, Kfar Saba, Israel, p.A1595 P160 Prevalence of Chronic Obstructive Pulmonary Disease with Preserved Ratio Impaired Spirometry (COPD-PRISM) and Clinical Outcomes in Tertiary Care Setting Thailand/ T. Kawamatawong, N. Rungsrisasithorn, W. Wudhikulprapan, W. Sukkasem, Bangkok, Thailand, p.A1596 P161 Improving Adherence to COPD Guidelines Is the Need of the Hour: Single Center Study on Rates of Influenza and Pneumococcus Vaccination/ S. Nuguru, A. Madhavan, D. Kosnar, K. Carney, New Brunswick, NJ, p.A1597 P162 Analysis of Bacterial and Viral Pathogens in Acute Exacerbation of Chronic Obstructive Pulmonary Disease According to Presence of Emphysematous Lesion/ J. Choi, J.Y. Oh, G.-Y. Hur, Y.S. Lee, S.Y. Lee, J.J. Shim, K.-H. Kang, K.H. Min, Seoul, Korea, Republic of, p.A1598 P163 Forced Vital Capacity (FVC) May Be an Independent Marker for Assessing Clinical Outcomes in Chronic Obstructive Pulmonary Disease (COPD)/ W. Seo, T.J. An, Seoul, Korea, Republic of, p.A1599 P164 Comorbidity and Quality of Life in the Patient with Chronic Obstructive Pulmonary Disease/ E.J. Soto Hurtado, J. Bujalance Zafra, L. García López, I. Millán Pinilla, R. Arroyo Morales, M. Bujalance Zafra, Malaga, Spain, p.A1600 P165 Relationship of Physical Activity Level with Musculoskeletal Conditions and Inflammation in COPD Patients Without Comorbidities/ S. Majima, K. Wakahara, T. Nishio, S. Nakamura, T. Sashio, S. Asano, Y. Hasegawa, Aichi, Japan, p.A1601 P166 Exacerbation Rate in COPD Patients - Two Years Follow-Up Cohort/ O.A. Nascimento, C.S. Silva, A.A. Albuquerque Neto, M. Gazzotti, J.R. Jardim, Sao Paulo, Brazil, p.A1602 P167 Chronic Obstructive Pulmonary Disease (COPD) Is an Independent Risk Factor of Surgical Complication in Patients Receiving Robotic-Assisted Coronary Artery Bypass Graft (RA-CABG)/ K.-Y. Chang, Z.-R. Zheng, Y. Chang, C.-H. Shen, M.C. Chan, Taichung, Taiwan, p.A1603 ATS 2019 • Dallas, TX 58 SUNDAY • MAY 19